Septerna

SEPN · NASDAQ

$39.35+$2.97 (+8.16%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $36.38

SEPN analyst rating

BuyConsensus of 7 analysts over the last 12 months. 100% rate it a buy.

Strong buy1
Buy6
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $56.10 (+42.6% upside)

Low: $49.49
Now: $39.35
High: $65.10

Upgrades and downgrades

The latest rating actions, newest first

SEPN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Aug 19, 2026	Maintains	Overweight	$38.00 → $48.00	44%
Jones Trading	Aug 13, 2026	Maintains	Buy	$43.00 → $62.00	21%
Wells Fargo	Aug 12, 2026	Maintains	Overweight	$48.00 → $50.00	54%
HC Wainwright & Co.	Aug 12, 2026	Maintains	Buy	$40.00 → $60.00	43%
Guggenheim	Aug 11, 2026	Maintains	Buy	$45.00 → $51.00	57%
Guggenheim	Jul 1, 2026	Maintains	Buy	$52.00 → $45.00	57%
HC Wainwright & Co.	Jul 1, 2026	Maintains	Buy	$40.00	43%
Truist Securities	Jul 1, 2026	Maintains	Buy	$35.00 → $43.00	51%
Raymond James	Jun 8, 2026	Maintains	Strong Buy	$47.00 → $53.00	60%
HC Wainwright & Co.	May 13, 2026	Maintains	Buy	$40.00	43%

The case for and against

Updated Oct 14, 2026

Bull case

Septerna is well positioned because its Native Complex Platform is producing differentiated oral small-molecule GPCR assets across endocrinology, immunology, inflammation, and metabolic disease, with multiple shots on goal in SEP-479, SEP-631, TSHR, and obesity partnerships. Lead asset SEP-479 has shown an approximately 3- to 4-day half-life that should support once-daily dosing, with Phase 1 data expected in 1Q27 and a strong preclinical package presented at ENDO 2026, while management expects cash to fund operations into at least 2029. The balance sheet is further supported by Novo Nordisk’s $195 million upfront payment and full R&D funding under their agreement, giving Septerna capital to advance programs and absorb clinical risk as it pursues high-unmet-need indications.

Bear case

Septerna is a clinical-stage biotech with no approved products, so value depends heavily on risky pipeline assets such as SEP-631, TSHR, and GLP-1R/GIPR/GCGR rather than current earnings or commercial cash flow. The DCF scenarios still assign only 15% to 30% approval probabilities and rely on 11% discount rates, signaling substantial clinical, regulatory, and partnership uncertainty, especially around Novo Nordisk and U.S.-only sales assumptions. Even under these relatively conservative inputs, the implied firm value of about $1.8B to $2.8B is fragile because setbacks in trials, delayed development, or long-term dilution could quickly undermine the thesis.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.